Halozyme Therapeutics, Inc.
HALO
$64.30
$1.762.81%
| Weiss Ratings | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Weak | |||
| Risk Grade | D+ | |||
| Reward Grade | B+ | |||
| Rating Factors | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Excellent | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.11 | |||
| Price History | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 4.65% | |||
| 30-Day Total Return | 13.26% | |||
| 60-Day Total Return | 37.28% | |||
| 90-Day Total Return | 9.50% | |||
| Year to Date Total Return | 33.93% | |||
| 1-Year Total Return | 57.56% | |||
| 2-Year Total Return | 84.66% | |||
| 3-Year Total Return | 72.85% | |||
| 5-Year Total Return | 331.54% | |||
| 52-Week High % Change | -4.57% | |||
| 52-Week Low % Change | 65.76% | |||
| Price | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $65.53 | |||
| 52-Week Low Price | $37.73 | |||
| 52-Week Low Price (Date) | Apr 18, 2024 | |||
| 52-Week High Price (Date) | Aug 29, 2024 | |||
| Valuation | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 7.70B | |||
| Enterprise Value | 8.64B | |||
| Price/Earnings (TTM) | 18.22 | |||
| Earnings Per Share (TTM) | 3.43 | |||
| Earnings Per Share Growth | 62.32% | |||
| Price/Earnings To Growth | 0.29 | |||
| Price/Sales (TTM) | 7.94 | |||
| Price/Book (Q) | 21.17 | |||
| Enterprise Value/Revenue (TTM) | 8.51 | |||
| Price | $64.30 | |||
| Enterprise Value/EBITDA (TTM) | 13.78 | |||
| Enterprise Value/EBIT | 15.67 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 128.98M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 794 8889 | |||
| Address | 12390 El Camino Real San Diego, CA 92130 | |||
| Website | halozyme.com | |||
| Country | United States | |||
| Year Founded | 1998 | |||
| Profitability | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 54.31% | |||
| Profit Margin | 43.73% | |||
| Management Effectiveness | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 18.16% | |||
| Return on Equity | 198.42% | |||
| Income Statement | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.02B | |||
| Total Revenue (TTM) | 1.02B | |||
| Revenue Per Share | $7.87 | |||
| Gross Profit (TTM) | 776.86M | |||
| EBITDA (TTM) | 627.09M | |||
| EBIT (TTM) | 551.48M | |||
| Net Income (TTM) | 444.09M | |||
| Net Income Avl. to Common (TTM) | 444.09M | |||
| Total Revenue Growth (Q YOY) | 29.55% | |||
| Earnings Growth (Q YOY) | 60.46% | |||
| EPS Diluted (TTM) | 3.43 | |||
| EPS Diluted Growth (Q YOY) | 62.31% | |||
| Balance Sheet | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 596.07M | |||
| Cash Per Share (Q) | $4.62 | |||
| Total Current Assets (Q) | 1.09B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 363.82M | |||
| Current Ratio (Q) | 7.803 | |||
| Book Value Per Share (Q) | $2.95 | |||
| Total Assets (Q) | 2.06B | |||
| Total Current Liabilities (Q) | 139.10M | |||
| Total Debt (Q) | 1.54B | |||
| Total Liabilities (Q) | 1.70B | |||
| Total Common Equity (Q) | 363.82M | |||
| Cash Flow | HALO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -262.72M | |||
| Cash from Financing (TTM) | -218.86M | |||
| Net Change in Cash (TTM) | -2.52M | |||
| Levered Free Cash Flow (TTM) | 402.01M | |||
| Cash from Operations (TTM) | 479.06M | |||
